Table of Contents Author Guidelines Submit a Manuscript


Call for Papers

Gliomas are a heterogeneous group of tumors developing from glial cells in the central nervous system. They include high-grade gliomas (such as glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, and anaplastic oligodendroglioma) and low-grade gliomas (such as pilocytic astrocytoma, grade II oligodendroglioma/astrocytoma/ependymoma, and diffuse astrocytoma).

In the last years, there have been important developments about their diagnosis, their biological mechanism, genetic mutations, and moreover, there have been numerous clinical trials regarding their treatment.

New technological instruments such as magnetic resonance imaging with spectroscopy and perfusion and positron emission tomography with methionine can help in the correct diagnosis for these tumors.

The recent discovery of IDH gene mutation in gliomas has been an important contribution to the knowledge of biological mechanism and prognosis of these tumors.

Antiangiogenic treatments for glioblastoma patients have been tested in numerous clinical trials, in particular, the role of bevacizumab as first or second line therapy.

We invite authors to submit original research and review articles that will stimulate the continuing efforts to understand the molecular pathology underlying gliomas, the development of new technological instruments for better diagnosis, and the development of new treatments and new knowledge about psychological approaches and supportive care for these patients and their caregivers. Potential topics include, but are not limited to:

  • Development of novel treatments, such as antiangiogenic drugs or vaccines, for gliomas
  • Advances in molecular mechanisms of gliomas
  • Developments of novel techniques in neurosurgery
  • Developments of molecular pathology in gliomas
  • Development of new prognostic and predictive factors in gliomas
  • Developments of new tools for diagnosis of gliomas
  • Recent advances in genetic mutations in gliomas
  • Advances in cancer stem cells in gliomas
  • Palliative care in neurooncology for patients with gliomas
  • Quality of life and neurocognitive functions in patients with gliomas

Before submission authors should carefully read over the journal's Author Guidelines which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Manuscript DueFriday, 28 March 2014
First Round of ReviewsFriday, 20 June 2014
Publication DateFriday, 15 August 2014

Lead Guest Editor

  • Giuseppe Lombardi, Medical Oncology 1, Venetian Institute of Oncology – IRCCS, Padua, Italy

Guest Editors

  • Roberta Rudà, Department of Neuro-Oncology, University Hospital, Torino, Italy
  • Alessandro Della Puppa, Department of Neurosurgery, Azienda Ospedaliera-Padua University, Padua, Italy
  • Andrea Pace, Neurology Unit at National Cancer Institute Regina Elena, Rome, Italy
  • Emeline Tabouret, Department of Neuro-Oncology, Hopitaux de Marseille, Marseille, France
  • Anna Luisa Di Stefano, Department of Neuro-Oncology, Université P8M Curie, GH Pitié-Salpêtrière, Paris